Formulation of Biotech Products, Including Biopharmaceutical Considerations

  • Daan J. A. Crommelin


This chapter deals with formulation aspects of pharmaceutical proteins. Both technological questions and biopharmaceutical issues such as the choice of the delivery systems, the route of administration, and possibilities for target site-specific delivery of proteins are considered.


Therapeutic Protein Continuous Glucose Monitoring Insulin Detemir Protein Drug Gemtuzumab Ozogamicin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Arakawa T, Kita Y, Carpenter JF (1991) Protein-solvent interactions in pharmaceutical formulation. Pharm Res 8:285–291PubMedCrossRefGoogle Scholar
  2. Bae YH, Park K (2011) Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 153:198–205PubMedCrossRefGoogle Scholar
  3. Banerjee PS, Hosny EA, Robinson JR (1991) Parenteral delivery of peptide and protein drugs. In: Lee VHL (ed) Peptide and protein drug delivery. Marcel Dekker, Inc., New York, pp 487–543Google Scholar
  4. Björk E, Edman P (1988) Characterization of degradable starch microspheres as a nasal delivery system for drugs. Int J Pharm 62:187–192CrossRefGoogle Scholar
  5. Brange J, Langkjaer L (1993) Insulin structure and stability. In: Wang YJ, Pearlman R (eds) Stability and characterization of protein and peptide drugs. Case histories. Plenum Press, Inc, New York, pp 315–350CrossRefGoogle Scholar
  6. Chien YW (1991) Transdermal route of peptide and protein drug delivery. In: Lee VHL (ed) Peptide and protein drug delivery. Marcel Dekker, Inc., New York, pp 667–689Google Scholar
  7. Choudhari S, Mathew M, Verma RS (2011) Therapeutic potential of anticancer immunotoxins. Drug Discov Today 16:495–503CrossRefGoogle Scholar
  8. Constantino HR, Pikal MJ (2004) Lyophilization of biopharmaceuticals. AAPS Press, ArlingtonGoogle Scholar
  9. Crommelin DJA, Schreier H (1994) Liposomes. In: Kreuter J (ed) Colloidal drug delivery systems. Marcel Dekker, Inc., New York, pp 73–190Google Scholar
  10. Crommelin DJA, Storm G (1990) Drug targeting. In: Sammes PG, Taylor JD (eds) Comprehensive medicinal chemistry. Pergamon Press, Oxford, pp 661–701Google Scholar
  11. Crommelin DJA, Bergers J, Zuidema J (1992) Antibody-based drug targeting approaches: perspectives and challenges. In: Wermuth CG, Koga N, König H, Metcalf BW (eds) Medicinal chemistry for the 21st century. Blackwell Scientific Publications, Oxford, pp 351–365Google Scholar
  12. Crommelin DJA, Scherphof G, Storm G (1995) Active targeting with particulate carrier systems in the blood compartment. Adv Drug Deliv Rev 17:49–60CrossRefGoogle Scholar
  13. De Leede LGJ, Humphries JE, Bechet AC, Van Hoogdalem EJ, Verrijk R, Spencer DJ (2008) Novel controlled-release Lemna-derived IFN-α2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. J Interferon Cytokine Res 28:113–122PubMedCrossRefGoogle Scholar
  14. Delves PJ, Martin MS, Burton DR, Roitt IM (2011) Roitt’s essential immunology, 12th edn. Wiley-Blackwell, OxfordGoogle Scholar
  15. Edman P, Björk E (1992) Nasal delivery of peptide drugs. Adv Drug Deliv Rev 8:165–177CrossRefGoogle Scholar
  16. Fendler JH (1980) Optimizing drug entrapment in liposomes. Chemical and biophysical considerations. In: Gregoriadis G, Allison AC (eds) Liposomes in biological systems. Wiley, Chichester, p 87Google Scholar
  17. Franks F, Hatley RHM, Mathias SF (1991) Materials science and the production of shelf-stable biologicals. Pharm Technol Int 3:24–34Google Scholar
  18. Gregoriadis G (2006) Liposome technology, 3rd edn. Informa Healthcare, New YorkCrossRefGoogle Scholar
  19. Groves M (1988) Parenteral technology manual. Interpharm Press, Inc., Buffalo GroveGoogle Scholar
  20. Halls NA (1994) Achieving sterility in medical and pharmaceutical products. Marcel Dekker, Inc., New YorkGoogle Scholar
  21. Heilmann K (1984) Therapeutic systems. Rate controlled delivery: concept and development. G. Thieme Verlag, StuttgartGoogle Scholar
  22. Heller J (1993) Polymers for controlled parenteral delivery of peptides and proteins. Adv Drug Deliv Rev 10:163–204CrossRefGoogle Scholar
  23. Hellström KE, Hellström I, Goodman GE (1987) Antibodies for drug delivery. In: Robinson JR, Lee VHL (eds) Controlled drug delivery. Marcel Dekker, Inc., New York, pp 623–653Google Scholar
  24. Hernández RM, Orive G, Murua A, Pedraz JL (2010) Microcapsules and microcarriers for in situ cell delivery. Adv Drug Deliv Rev 62:711–730PubMedCrossRefGoogle Scholar
  25. Holmes D (2011) Buy buy bispecific antibodies. Nat Rev Drug Discov 10:798–800PubMedCrossRefGoogle Scholar
  26. Hovorka R (2011) Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 7:385–395PubMedCrossRefGoogle Scholar
  27. Hunt CA, MacGregor RD, Siegel RA (1986) Engineering targeted in vivo drug delivery. I. The physiological and physicochemical principles governing opportunities and limitations. Pharm Res 3:333–344CrossRefGoogle Scholar
  28. Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47:3039–3051PubMedGoogle Scholar
  29. Jorgensen J, Nielsen HM (2009) Delivery technologies for biopharmaceuticals: peptides, proteins, nucleic acids and vaccines. Wiley, ChichesterCrossRefGoogle Scholar
  30. Kersten G, Hirschberg H (2004) Antigen delivery systems. Expert Rev Vaccines 3:89–99CrossRefGoogle Scholar
  31. Kim SW, Pai CM, Makino K, Seminoff LA, Holmberg DL, Gleeson JM, Wilson DA, Mack EJ (1990) Self-regulated glycosylated insulin delivery. J Control Release 11:193–201CrossRefGoogle Scholar
  32. Kis EE, Winter G, Myschik J (2012) Devices for intradermal vaccination. Vaccine 30:523–538PubMedCrossRefGoogle Scholar
  33. Klegerman ME, Groves MJ (1992) Pharmaceutical biotechnology: fundamentals and essentials. Interpharm Press, Inc., Buffalo GroveGoogle Scholar
  34. Kumar S, Char H, Patel S, Piemontese D, Malick AW, Iqbal K, Neugroschel E, Behl CR (1992) In vivo transdermal iontophoretic delivery of growth hormone releasing factor GRF (1–44) in hairless guinea pigs. J Control Release 18:213–220CrossRefGoogle Scholar
  35. Lammers T, Hennink WE, Storm G (2008) Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99:392–397PubMedCrossRefGoogle Scholar
  36. Maberly GF, Wait GA, Kilpatrick JA, Loten EG, Gain KR, Stewart RDH, Eastman CJ (1982) Evidence for insulin degradation by muscle and fat tissue in an insulin resistant diabetic patient. Diabetol 23:333–336CrossRefGoogle Scholar
  37. Mastrobattista E, van der Aa MAEM, Hennink WE, Crommelin DJA (2006) Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov 5:115–121PubMedCrossRefGoogle Scholar
  38. Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5:905–916PubMedCrossRefGoogle Scholar
  39. Moeller EH, Jorgensen L (2009) Alternative routes of administration for systemic delivery of protein pharmaceuticals. Drug Discovery Today: Technologies 5:89–94CrossRefGoogle Scholar
  40. Nässander UK, Storm G, Peeters PAM, Crommelin DJA (1990) Liposomes. In: Chasin M, Langer R (eds) Biodegradable polymers as drug delivery systems. Marcel Dekker, New York, pp 261–338Google Scholar
  41. Nguyen TH, Ward C (1993) Stability characterization and formulation development of alteplase, a recombinant tissue plasminogen activator. In: Wang YJ, Pearlman R (eds) Stability and characterization of protein and peptide drugs. Case histories. Plenum Press, New York, pp 91–134CrossRefGoogle Scholar
  42. O’Hagan DT (1990) Intestinal translocation of particulates - implications for drug and antigen delivery. Adv Drug Deliv Rev 5:265–285CrossRefGoogle Scholar
  43. Patton JS, Trinchero P, Platz RM (1994) Bioavailability of pulmonary delivered peptides and proteins: alpha-interferon, calcitonin and parathyroid hormones. J Control Release 28:79–85CrossRefGoogle Scholar
  44. Patton JS, Bukar JG, Eldon MA (2004) Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 43:781–801PubMedCrossRefGoogle Scholar
  45. Pearlman R, Bewley TA (1993) Stability and characterization of human growth hormone. In: Wang YJ, Pearlman R (eds) Stability and characterization of protein and peptide drugs. Case histories. Plenum Press, New York, pp 1–58CrossRefGoogle Scholar
  46. Peeters PAM, Storm G, Crommelin DJA (1987) Immunoliposomes in vivo: state of the art. Adv Drug Deliv Rev 1:249–266CrossRefGoogle Scholar
  47. Pikal MJ (1990) Freeze-drying of proteins. Part I: process design. BioPharm 3(8):18–27Google Scholar
  48. Poste G (1985) Drug targeting in cancer therapy. In: Gregoriadis G, Poste G, Senior J, Trouet A (eds) Receptor-mediated targeting of drugs. Plenum Press, New York, pp 427–474Google Scholar
  49. Pristoupil TI (1985) Haemoglobin lyophilized with sucrose: effect of residual moisture on storage. Haematologia 18:45–52PubMedGoogle Scholar
  50. Roy MJ (2011) Biotechnology operations: principles and practices. CRC Press, Boca RatonGoogle Scholar
  51. Sage BH, Bock CR, Denuzzio JD, Hoke RA (1995) Technological and developmental issues of iontophoretic transport of peptide and protein drugs. In: Lee VHL, Hashida M, Mizushima Y (eds) Trends and future perspectives in peptide and protein drug delivery. Harwood Academic Publishers GmbH, Chur, pp 111–134Google Scholar
  52. Schaepelynck P, Darmon P, Molines L, Jannot-Lamotte MF, Treglia C, Raccah D (2011) Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps. Diabetes Metab 37:S85–S93PubMedCrossRefGoogle Scholar
  53. Stenekes R (2000) Nanoporous dextran microspheres for drug delivery. Thesis, Utrecht UniversityGoogle Scholar
  54. Storm G, Crommelin DJA (1998) Liposomes: quo vadis? Pharm Sci Tech Today 1:19–31CrossRefGoogle Scholar
  55. Storm G, Oussoren C, Peeters PAM, Barenholz YB (1993) Tolerability of liposomes in vivo. In: Gregoriadis G (ed) Liposome technology. CRC Press, Inc, Boca Raton, pp 345–383Google Scholar
  56. Storm G, Nässander U, Vingerhoeds MH, Steerenberg PA, Crommelin DJA (1994) Antibody-targeted liposomes to deliver doxorubicin to ovarian cancer cells. J Liposome Res 4:641–666CrossRefGoogle Scholar
  57. Supersaxo A, Hein WR, Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7:167–169PubMedCrossRefGoogle Scholar
  58. Thurow H, Geisen K (1984) Stabilization of dissolved proteins against denaturation at hydrophobic interfaces. Diabetologia 27:212–218PubMedGoogle Scholar
  59. Tomlinson E (1987) Theory and practice of site-specific drug delivery. Adv Drug Deliv Rev 1:87–198CrossRefGoogle Scholar
  60. Traitel T, Goldbart R, Kost J (2008) Smart polymers for responsive drug-delivery systems. J Biomater Sci Polym Ed 19:755–767PubMedCrossRefGoogle Scholar
  61. Tresco PA (1994) Encapsulated cells for sustained neurotransmitter delivery to the central nervous system. J Control Release 28:253–258CrossRefGoogle Scholar
  62. USP 29/NF 24 through second supplement (2006) United States Pharmacopeial Convention, RockvilleGoogle Scholar
  63. Vemuri S, Yu CT, Roosdorp N (1993) Formulation and stability of recombinant alpha1-antitrypsin. In: Wang YJ, Pearlman R (eds) Stability and characterization of protein and peptide drugs. Plenum Press, New York, pp 263–286CrossRefGoogle Scholar
  64. Wang YJ, Watson MA (1988) Parenteral formulations of proteins and peptides: stability and stabilizers. J Parenter Sci Technol 42(Suppl 4S):1–26Google Scholar
  65. Woodle M, Newman M, Collins L, Redemann C, Martin F (1990) Improved long-circulating (Stealth®) liposomes using synthetic lipids. Proc Int Symp Contr Rel Bioact Mater 17:77–78Google Scholar
  66. Zhou XH, Li Wan Po A (1991a) Peptide and protein drugs: I. Therapeutic applications, absorption and parenteral administration. Int J Pharm 75:97–115CrossRefGoogle Scholar
  67. Zhou XH, Li Wan Po A (1991b) Peptide and protein drugs: II. Non-parenteral routes of delivery. Int J Pharm 75:117–130CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical SciencesUtrecht UniversityUtrechtThe Netherlands

Personalised recommendations